- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
1735
Phenotypic Characteristics of PD-1, CTLA-4 and FoxP3 Expression during Tenofovir therapy in Chronic Hepatitis B
Hyosun Cho1, Chang Wook Kim2, Yu seung Kim2, Hee Yeon Kim2, Jong Young Choi2, Seung Kew Yoon2, Chang Don Lee3;
1Pharmacy, Duksung Women's University, Seoul, Republic of Korea; 2Internal Medicine, The Catholic University of Korea, Uijeonbu-shi, Republic of Korea; 3Internal Medicine, International St. Mary's Hospital, Incheon, Republic of Korea
Background: Inhibitory molecules such as programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) are associated with antiviral effector T-cell dysfunction, which influences on T-cell exhaustion and persistent viral infection. These PD-1 and CTLA-4 are up-regulated in chronic viral infection such as chronic hepatitis C, chronic hepatitis B and human immunodeficiency virus infection but there is few report about the role of PD-1 and CTLA-4 in patients with chronic hepatitis B during antiviral therapy with tenofovir. We investigated the expression of PD-1 and CTLA-4 during tenofovir treatment in patients with chronic hepatitis B. Methods: Nine patients with chronic hepatitis B under tenofovir treatment were enrolled for detection of intrinsic inhibitory molecules of T cell signals (PD-1, CTLA-4) and extrinsic inhibitory molecule, FoxP3. Peripheral blood mononuclear cells (PBMC) were isolated from these subjects before tenofovir treatment (T0) and 1 month (T1), 3 month (T3), 6 month (T6) during tenofovir treatment. The expressions of PD-1, CTLA-4 and FoxP3 on T cells were monitored by flow cytometry. Results: T cells from patients with chronic hepatitis B under tenofovir treatment showed decreased expression of PD-1, CTLA-4, and FoxP3 at T6 compared to T0 (%PD-1/ CD8, 5.0 ± 2.2 vs. 4.0 ± 1.2; %CTLA-4/CD8, 1.7 ± 0.9 vs. 1.2 ± 0.6; %FoxP3/CD4, 7 ± 2.5 vs. 6.1 ± 2.6 showed as mean ± SD). During the initial phase of tenofovir treatment, FoxP3 and PD-1 fluctuate at T1 and T3 but, CTLA-4 decreased steadily even at T1 and T3. Conclusions: In chronic hepatitis B, PD-1 and CTLA-4 as inhibitory T cell molecules and FoxP3 as regulatory T cell marker are down-regulated during initial 6 month tenofovir therapy, which could restore HBV-specific T cell function during tenofovir antiviral therapy. Long-term effects of tenofovir on host immune system are needed to be elucidate.
Disclosures:
Chang Wook Kim - Consulting: Gilead, MSD; Grant/Research Support: BMS, Handok, Pharmicell, Pharmaking; Speaking and Teaching: BMS, Donga, Dae-woong
The following people have nothing to disclose: Hyosun Cho, Yu seung Kim, Hee Yeon Kim, Jong Young Choi, Seung Kew Yoon, Chang Don Lee
|
|